| Cat. No. |
Product Name |
Information |
| PC-22912 |
Bemnifosbuvir
HCV inhibitor
|
Bemnifosbuvir (AT-527, RG-6422) is a novel phosphoramidate prodrug of AT-511 that has potent in vitro activity against HCV (EC50=5-28 nM), also inhibits replication of SARS-CoV-2 with EC90 of 0.47 uM. |
| PC-21354 |
Ledipasvir
HCV NS5A inhibitor
|
Ledipasvir (GS-5885) is a potent, selective and oral HCV NS5A inhibitor with EC50 of 31 pM and 4 pM against GT1a and GT1b, respectively. |
| PC-20275 |
Nesbuvir
HCV NS5B inhibitor
|
Nesbuvir (HCV-796) is a selective, non-nucleoside HCV nonstructural protein 5B (NS5B) polymerase inhibitor with IC50 of 0.01-0.14 uM for genotype 1, EC50 of 5 nM and 9 nM against genotype 1a and 1b replicon. |
| PC-73081 |
Amphihevir
HCV NS4B inhibitor
|
Amphihevir is a potent, selective HCV NS4B inhibitor with EC50 of 0.34 and 1.97 nM against the GT1a (H77) and GT1b replicon in luciferase assays. |
| PC-72892 |
Dichlorcyclizine
HCV entry inhibitor
|
Dichlorcyclizine (DCCZ) is a potent, small molecule HCV fusion inhibitor, also inhibits SARS-CoV and SARS-CoV-2 S-mediated infection with EC50 of 9.92 and 4.53 uM, respectively. |
| PC-72891 |
Fluoxazolevir
HCV entry inhibitor
|
Fluoxazolevir (NCGC00351982) is a potent, small molecule entry inhibitor of HCV with EC50 of 18.8 nM. |
| PC-72626 |
AT-527
HCV inhibitor
|
AT-527 (AT527, Bemnifosbuvir hemisulfate, RG-6422) is a novel phosphoramidate prodrug of AT-511 that has potent in vitro activity against HCV (EC50=5-28 nM), also inhibits replication of SARS-CoV-2 with EC90 of 0.47 uM. |
| PC-72397 |
GSK2818713
HCV NS5A inhibitor
|
GSK2818713 (GSK-2818713) is a nonstructural protein 5A (NS5A) HCV inhibitor with broad genotype coverage. |
| PC-35585 |
Cyclophilin inhibitor C31
Cyclophilin inhibitor, HCV inhibitor
|
Cyclophilin inhibitor C31 (SMCypI C31) is a small-molecule cyclophilin (CypA) inhibitor (SMCypI) with PPIase inhibition IC50 of 0.1 uM, displays anti-HCV activity (HCV Gt1b replicon EC50=0.4 uM) and disrupts the CypA-NS5A interaction. |
| PC-35444 |
Coblopasvir
HCV NS5A inhibitor
|
Coblopasvir (KW136, KW-136) is a novel HCV NS5A inhibitor under development for treatment of HCV infection. |
| PC-35056 |
Ciluprevir
HCV NS3/4A inhibitor
|
Ciluprevir (BILN2061) is a potent HCV NS3/4A protease inhibitor with Ki of 0.66 and 0.30 nM for NS3-NS4A protease of HCV 1b and HCV 1a, respectively. |
| PC-35032 |
BI-1388
HCV NS3 protease inhibitor
|
BI-1388 is a potent, specific, macrocyclic inhibitor of HCV NS3 protease, inhibits viral replication for various HCV genotypes and for resistant mutants D168V and R155K. |
